Table 1.
Donor cells | Injection site | Hepatic injury | Outcome | Cell tracking | References |
50 × 106 free or encapsulated congeneic Hc | Peritoneum | None | 34.8% serum bilirubin reduction with encapsulated Hc vs 13.5% with free Hc at 1 mo | Light and electron microscopy | 22 |
10 × 106 syngeneic Hc | Liver | Hepatectomy | Significant reduction of serum bilirubin up to 4 wk | ND | 24 |
Apparition of conjugates in bile | |||||
10 × 106 congeneic Hc | Spleen | None | Significant reduction of serum bilirubin up to 12 mo | ND | 27 |
Apparition of bile conjugates at 4 mo | |||||
2-20 × 106 congeneic Hc | Portal vein | Right portal vein ligation | Significant reduction of serum bilirubin when injury with 2 × 106 Hc or with 20 × 106 without injury up to 30 d | UGT1A1 activity, WB, PCR for ugt1 gene | 28 |
Conjugates in bile after 10 d | |||||
5 × 106 congeneic Hc | Spleen | Hepatic irradiation ± Hepatectomy | Normalization of serum bilirubin only with combined injury | UGT1A1 activity, WB, IHC | 29 |
Conjugates in bile detected up to 5 mo | |||||
10 × 106 congeneic Hc | Spleen | Hepatic irradiation ± FasL-induced apoptosis | Normalization of serum bilirubin up to 160 d | UGT1A1 activity, WB, IHC | 31 |
Conjugates in bile at 150 d | |||||
Estimation of repopulation at 52 ± 15% when combined injury | |||||
40 × 106 fetal or adult syngeneic Hc | Spleen | Retrorsine + Triiodothyronine | Significant reduction of serum bilirubin (+ conjugates in bile) up to 90 d (no difference between fetal and adult cells) | PCNA | 32 |
Hc: Hepatocyte; IHC: Immunohistochemistry; PCNA: Proliferating cell nuclear antigen; WB: Western blot.